| Name | Title | Contact Details |
|---|
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Clear Cycle is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Transave is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At VAYA Pharma, we are committed to improving quality of life and delivering products that exemplify our key values. VAYA Pharma`s history of clinical research is based on understanding the potential of the human body in order to reform medicine. Through this research, we have discovered a strong correlation between certain disorders and lipid imbalances in affected individuals. Because of this, VAYA Pharma focuses on developing innovations for the clinical dietary management of disorders that are specifically associated with lipid imbalances. Our products deliver a nutritional based solution that are familiar to the human body and clinically proven to be safe and effective with virtually no side effects. Using lipid-based ingredients, our innovative products address nutritional needs of people with health conditions that cannot be met through modification of diet alone.